Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VVD-130037 in Advanced Solid Tumors
NCT05954312Phase 1Recruiting
- Sponsor
- Vividion Therapeutics
- Start
- Jul 2023
- Primary completion
- Aug 2030
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of VVD-130037 in solid tumor, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 1 more (7 arms), sponsored by Vividion Therapeutics. Primary endpoints: Dose-limiting Toxicities at Day 28 and Adverse Events up to 4 years. Started Jul 2023; status: recruiting.
02
Drugs
VVD-130037
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05954312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05954312.